Literature DB >> 26970364

Synthetic Cannabinoids-Further Evidence Supporting the Relationship Between Cannabinoids and Psychosis.

Liana Fattore1.   

Abstract

Consumption of synthetic mind-altering compounds, also known as "new psychoactive substances," is increasing globally at an alarming rate. Synthetic cannabinoids (SCs) are among the most commonly used new psychoactive substances. They are usually purchased as marijuana-like drugs, marketed as herbal blends and perceived as risk-free by inexperienced users. Yet, contrary to Δ(9)-tetrahydrocannabinol, SCs may lead to severe health consequences, including anxiety, tachycardia, hallucinations, violent behavior, and psychosis. This review focuses on the latest (2010-2015) evidence of psychotic symptoms induced by ingestion of products containing SCs. Reports suggesting that SCs may either exacerbate previously stable psychotic symptoms (in vulnerable individuals) or trigger new-onset psychosis (in individuals with no previous history of psychosis) are reviewed. Pharmacology and toxicology of these compounds are discussed, with particular reference to their psychoactive effects.
Copyright © 2016 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Herbal blends; Intoxication; Novel psychoactive substances; Psychosis; Spice; Synthetic cannabinoids

Mesh:

Substances:

Year:  2016        PMID: 26970364     DOI: 10.1016/j.biopsych.2016.02.001

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  38 in total

1.  Positive Allosteric Modulation of the 5-HT1A Receptor by Indole-Based Synthetic Cannabinoids Abused by Humans.

Authors:  Hideaki Yano; Pramisha Adhikari; Sett Naing; Alexander F Hoffman; Michael H Baumann; Carl R Lupica; Lei Shi
Journal:  ACS Chem Neurosci       Date:  2020-04-30       Impact factor: 4.418

Review 2.  The Bridge Between Classical and "Synthetic"/Chemical Psychoses: Towards a Clinical, Psychopathological, and Therapeutic Perspective.

Authors:  Laura Orsolini; Stefania Chiappini; Duccio Papanti; Domenico De Berardis; John M Corkery; Fabrizio Schifano
Journal:  Front Psychiatry       Date:  2019-11-20       Impact factor: 4.157

3.  Hospital Stay in Synthetic Cannabinoid Users With Bipolar Disorder, Schizophrenia, or Other Psychotic Disorders Compared With Cannabis Users.

Authors:  Huiqiong Deng; Pratikkumar V Desai; Satyajit Mohite; Olaoluwa O Okusaga; Xiang Yang Zhang; David A Nielsen; Thomas R Kosten
Journal:  J Stud Alcohol Drugs       Date:  2019-03       Impact factor: 2.582

4.  Identification of 'Voodoo': an emerging substance of abuse in Egypt.

Authors:  Rania Hussien; Sarah Ahmed; Hanem Awad; Maged El-Setouhy; Mohamed El-Shinawi; Jon Mark Hirshon
Journal:  Int J Environ Anal Chem       Date:  2020-01-16       Impact factor: 2.826

Review 5.  Marijuana Use and Organ Transplantation: a Review and Implications for Clinical Practice.

Authors:  Harinder Singh Rai; Gerald Scott Winder
Journal:  Curr Psychiatry Rep       Date:  2017-10-27       Impact factor: 5.285

Review 6.  Substance-induced Psychosis in Youth.

Authors:  David Beckmann; Kelsey Leigh Lowman; Jessica Nargiso; James McKowen; Lisa Watt; Amy M Yule
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2019-09-23

7.  Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis.

Authors:  Robin M Murray; Harriet Quigley; Diego Quattrone; Amir Englund; Marta Di Forti
Journal:  World Psychiatry       Date:  2016-10       Impact factor: 49.548

8.  Clinical characteristics of synthetic cannabinoid-induced psychosis in relation to schizophrenia: a single-center cross-sectional analysis of concurrently hospitalized patients.

Authors:  Merih Altintas; Leman Inanc; Gamze Akcay Oruc; Selim Arpacioglu; Huseyin Gulec
Journal:  Neuropsychiatr Dis Treat       Date:  2016-08-02       Impact factor: 2.570

9.  Psychiatric symptoms and synthetic cannabinoid use: Information for clinicians.

Authors:  Gary Sweet; Sara Kim; Samuel Martin; Nicole B Washington; Nancy Brahm
Journal:  Ment Health Clin       Date:  2018-03-26

Review 10.  Pro-Inflammatory Cytokines: Potential Links between the Endocannabinoid System and the Kynurenine Pathway in Depression.

Authors:  Ferenc Zádor; Sâmia Joca; Gábor Nagy-Grócz; Szabolcs Dvorácskó; Edina Szűcs; Csaba Tömböly; Sándor Benyhe; László Vécsei
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.